- Conditions
- Trauma to the Arm, Shoulder, Elbow, Forearm, or Hand
- Interventions
- Ultrasound (Sonosite Titan T-shaped ultrasound probe), Electrical Nerve Stimulation (Stimuplex (B Braun) needle)
- Device
- Lead sponsor
- Allentown Anesthesia Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Allentown, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 33,591
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Complicated Urinary Tract Infections
- Interventions
- Ceftazidime -avibactam, Cefepime
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- San Diego, California • Winston-Salem, North Carolina • Toledo, Ohio
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- PF-06252616
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 18 Years · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sacramento, California • Iowa City, Iowa + 9 more
- Conditions
- Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
- Interventions
- Denosumab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Wilmington, Delaware • Indianapolis, Indiana + 3 more
- Conditions
- Sarcoma
- Interventions
- Trabectedin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 15 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 31
- States / cities
- Anchorage, Alaska • San Diego, California • Santa Monica, California + 28 more
- Conditions
- Amyloidosis
- Interventions
- Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg, Daratumumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Duarte, California • San Francisco, California + 22 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Kinezodianone R hydrochloride, Placebo
- Drug
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Glioblastoma
- Interventions
- Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
- Drug · Other
- Lead sponsor
- Diffusion Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 13
- States / cities
- Irvine, California • Redwood City, California • Santa Monica, California + 10 more
- Conditions
- Malignant Lymphoma, Stem Cell Type, Autologous Transplant
- Interventions
- bortezomib and G-CSF
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Westwood, Kansas
- Conditions
- Relapsed/Refractory Small Cell Lung Cancer
- Interventions
- BMS-986525, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Buffalo, New York • Durham, North Carolina + 2 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- XmAb5574
- Biological
- Lead sponsor
- Xencor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Augusta, Georgia • Columbus, Ohio • Nashville, Tennessee
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy
- Interventions
- CBG/CBD Oil
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
- Interventions
- branebrutinib, abatacept, branebrutinib placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Covina, California • Encino, California + 35 more
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Interventions
- Xanamem, Placebo
- Drug
- Lead sponsor
- Actinogen Medical
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
- Conditions
- Healthy
- Interventions
- CS8080, Placebo
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Neptune City, New Jersey
- Conditions
- Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
- Interventions
- 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, TRU-016 6-20 mg/kg + idelalisib + rituximab, TRU-016 10-20 mg/kg + ibrutinib, TRU-016 10-20 mg/kg + bendamustine
- Biological
- Lead sponsor
- Aptevo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 8
- States / cities
- Augusta, Georgia • Columbus, Ohio • Philadelphia, Pennsylvania + 4 more
- Conditions
- Alzheimer Disease
- Interventions
- NNI-362, Placebo
- Drug
- Lead sponsor
- Neuronascent, Inc.
- Industry
- Eligibility
- 50 Years to 72 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Meningococcal Disease, Pregnancy, Infections, Meningococcal
- Interventions
- Meningococcal quadrivalent CRM-197 conjugate vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Wilmington, North Carolina
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- NMD670, Placebo
- Drug
- Lead sponsor
- NMD Pharma A/S
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 8
- States / cities
- Kansas City, Kansas • Boston, Massachusetts • Columbia, Missouri + 5 more
- Conditions
- Renal Dialysis, Pharmacokinetics
- Interventions
- PD-0332334
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Chronic Non-malignant Pain
- Interventions
- Buprenorphine transdermal patch, Placebo to match BTDS
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Trumbull, Connecticut • Clearwater, Florida + 17 more
- Conditions
- Hyperkalemia
- Interventions
- Patiromer
- Drug
- Lead sponsor
- Vifor Pharma, Inc.
- Industry
- Eligibility
- 0 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
- Conditions
- Cancer, Neoplasm
- Interventions
- SAR444881, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Duarte, California • Aurora, Colorado + 6 more
- Conditions
- Multiple Sclerosis
- Interventions
- Mycophenolate Mofetil (cellcept)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 21 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Dallas, Texas